Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubi-cin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previ-ously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study.

Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, JP; Her-baux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Miguel, J; Burgues, B; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Abrisqueta, P; Gau, JP; Hirata, J; Jiang, YW; Yan, M; Lee, C; Flowers, C; Salles, G; Collins, G. BRIT J HAEMATOL. 2022; 197: 14-16.

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC

von der Heyde, E; Burkle, D; Forstbauer, H; Hubner, G; Schmidt, B; Schroder, J; Distelrath, A; Wierecky, J; Stubs, P; Kisro, J; Welslau, M; Muller-Huesmann, H; Gohler, T; Krammer-Steiner, B; Schwaner, I; Hering-Schubert, C; Gerger, A; Greil, R; Jacobasch, L; Reichenbach, F; Stintzing, S; Prager, G. ANN ONCOL. 2022; 33: S248-S248.

Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).

Aggarwal, RR; Rottey, S; Aparicio, A; Greil, R; Reimers, MA; Sandhu, SK; Zhang, YR; Salvati, M; Sadraei, NH. J CLIN ONCOL. 2022; 40(6): DOI: 10.1200/JCO.2022.40.6_suppl.TPS197 Journal of Clinical Oncology 40, no. 6_suppl

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Ader, F; Bouscambert-Duchamp, M; Hites, M; Peiffer-Smadja, N; Poissy, J; Belhadi, D; Diallo, A; Lê, MP; Peytavin, G; Staub, T; Greil, R; Guedj, J; Paiva, JA; Costagliola, D; Yazdanpanah, Y; Burdet, C; Mentré, F. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14.

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.

Burtness, B; Rischin, D; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyr-ri, A; Brana, I; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Ge, J; Swaby, RF; Gu-muscu, B; Harrington, K. J Clin Oncol. 2022 Jul 20;40(21):2321-2332. doi: 10.1200/JCO.21.02198. E-pub 2022 Mar 25.

Detecting Bacterial-Human Lateral Gene Transfer in Chronic Lymphocy-tic Leukemia.

Akimova, E; Gassner, FJ; Greil, R; Zaborsky, N; Geisberger, R. Int J Mol Sci. 2022 Jan 20;23(3):1094. doi: 10.3390/ijms23031094.

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

Bishop, MR; Dickinson, M; Purtill, D; Barba, P; Santoro, A; Hamad, N; Kato, K; Sureda, A; Greil, R; Thieblemont, C; Morschhauser, F; Janz, M; Flinn, I; Rabitsch, W; Kwong, YL; Kersten, MJ; Minnema, MC; Holte, H; Chan, EHL; Martinez-Lopez, J; Muller, AMS; Maziarz, RT; McGuirk, JP; Bachy, E; Le Gouill, S; Dreyling, M; Harigae, H; Bond, D; Andreadis, C; McSweeney, P; Kharfan-Dabaja, M; Newsome, S; Degtyarev, E; Awasthi, R; del Corral, C; Andreola, G; Masood, A; Schuster, SJ; Jager, U; Borchmann, P; Westin, JR. N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596. Epub 2021 Dec 14.

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from Dis-CoVeRy and the EU-SolidAct EU response group.

Diallo, A; Troseid, M; Simensen, VC; Boston, A; Demotes, J; Olsen, IC; Chung, F; Paiva, JA; Hites, M; Ader, F; Arribas, JR; Baratt-Due, A; Melien, O; Tacconelli, E; Staub, T; Greil, R; Tsiodras, S; Briel, M; Esperou, H; Mentre, F; Eustace, J; Saillard, J; Delmas, C; LeMestre, S; Dumousseaux, M; Costaglio-la, D; Rottingen, JA; Yazdanpanah, Y. Clin Microbiol Infect. 2022 Jan;28(1):1-5. doi: 10.1016/j.cmi.2021.10.011. E-pub 2021 Nov 8.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lym-phoma.

Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, JP; Herbaux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Bergua-Burgues, JM; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Ab-risqueta, P; Gau, JP; Hirata, J; Jiang, YW; Yan, M; Lee, C; Flowers, CR; Sal-les, G. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.

Evaluating a Targeted Cancer Therapy Approach Mediated by RNA.

Woess, K; Sun, Y; Morio, H; Stierschneider, A; Kaufmann, A; Hainzl, S; Tratt-ner, L; Kocher, T; Tockner, B; Leb-Reichl, V; Steiner, M; Brachtl, G; South, AP; Bauer, JW; Reichelt, J; Furihata, T; Wally, V; Koller, U; Piñón Hofbauer, J; Guttmann-Gruber, C. Int J Mol Sci. 2022 Jan 5;23(1):575. doi: 10.3390/ijms23010575.